Ilyang Pharm (007570) — Cash Flow-to-Debt Ratio
Ilyang Pharm (007570) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2025, meaning its operating cash flow of ₩2.26 Billion could theoretically repay 0% of its total liabilities (₩205.41 Billion) in one year. Explore 007570 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ilyang Pharm Cash Flow-to-Debt Ratio (2003–2024)
Historical debt coverage capacity for Ilyang Pharm across 13 annual periods. Also explore Ilyang Pharm assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Ilyang Pharm (2003–2024)
Year-by-year debt coverage analysis for Ilyang Pharm. For market capitalisation and broader financial context, see Ilyang Pharm market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | ₩5.61 Billion | ₩189.63 Billion | ▼ -64.4% |
| 2023 | 0.08x | ₩13.34 Billion | ₩160.25 Billion | ▼ -42.6% |
| 2022 | 0.15x | ₩29.94 Billion | ₩206.33 Billion | ▼ -51.8% |
| 2021 | 0.30x | ₩67.02 Billion | ₩222.51 Billion | ▲ +1.8% |
| 2020 | 0.30x | ₩57.48 Billion | ₩194.19 Billion | ▲ +75.6% |
| 2019 | 0.17x | ₩36.19 Billion | ₩214.72 Billion | ▲ +69.5% |
| 2018 | 0.10x | ₩22.12 Billion | ₩222.37 Billion | ▼ -25.3% |
| 2017 | 0.13x | ₩30.03 Billion | ₩225.39 Billion | ▲ +5.6% |
| 2016 | 0.13x | ₩26.98 Billion | ₩213.91 Billion | ▼ -30.9% |
| 2015 | 0.18x | ₩40.27 Billion | ₩220.62 Billion | ▲ +142.4% |
| 2014 | 0.08x | ₩18.63 Billion | ₩247.37 Billion | ▲ +632.0% |
| 2013 | -0.01x | ₩-3.04 Billion | ₩214.50 Billion | ▼ -112.8% |
| 2003 | 0.11x | ₩10.08 Billion | ₩91.16 Billion | — |